When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AZRX - AzurRx initiates new mid-stage study of MS1819-SD in cystic fibrosis; shares up 12% after hours
AzurRx BioPharma Inc.
Thinly traded nano cap AzurRx BioPharma (NASDAQ:AZRX) is up 12% after hours on light volume in response to the launch of a Phase 2 clinical trial evaluating MS1819-SD, combined with standard porcine enzyme replacement therapy (PERT), in cystic fibrosis patients with severe exocrine pancreatic insufficiency who continue to experience clinical symptoms of fat malabsorption despite maximum PERT therapy. Preliminary data should be available in early 2020. The trial should be completed later that year.
More news on: AzurRx BioPharma, Inc., Healthcare stocks news, Stocks on the move,